Abstract Details

Title Comparing Brain MRI-derived Whole Brain and Grey Matter Volumes with Patient Reported Outcomes in a Cohort of People Living with MS

Topic Multiple Sclerosis

Presentation(s) P3 - Poster Session 3 (11:45 AM-12:45 PM)

Poster/Presentation
Number 1-013

Objective To assess the relationship between MRI-derived grey matter and whole brain volumes with patient reported outcomes (PROs) of depression, anxiety, and fatigue in people living with MS (pwMS).

Background Although patient reported outcomes of disability have been associated with worsening clinical disease in people with MS, our understanding of the relationship between PROs and structural changes in the brain remains limited.

Design/Methods Patient information (MS subtype, time since diagnosis) and patient reported outcomes (PHQ-9, GAD7, MSQOL-54, MFIS, ESS, PES) were collected from the Stanford ProjectBIG registry. Imaging volumetric data was collected from Icometrix MRI brain volume reports. Correlations between imaging volumes and PROs were assessed using the Pearson correlation coefficient. All analyses were processed using SPSS 29.0 statistical software.

Results Corrected grey matter volumes were positively correlated with mental MS quality of life in all people with MS (n = 110, r = 0.199, p = 0.039) and with progressive forms of MS (n = 24; r = 0.411, p = 0.046). However, grey matter volumes were not correlated with mental MS quality of life in people with relapsing MS, and grey matter volumes were not associated with any other PROs measures of depression, fatigue, pain, anxiety, or sleepiness among all people with MS or associated subtypes. Notably, corrected whole brain matter volumes were negatively correlated with PHQ9 depression score in all people with MS (r = -0.192, p = 0.016) and people with progressive MS (r = -0.447, p = 0.028), but corrected whole brain matter volumes were similarly not associated with any other PROs measures.

Conclusions

In people living with MS, corrected grey and whole matter volumes were correlated with worsened subjective mental quality of life and depression scores, respectively. However, no other correlations of significance were identified between brain volumes and patient reported outcomes in this study.

Authors/Disclosures
Garrett M. Timmons, MD (Stanford Neurology) PRESENTER	Dr. Timmons has nothing to disclose.
Anna J. Tomczak, MSc (Stanford)	Miss Tomczak has nothing to disclose.
Jeffrey E. Dunn, MD, FAAN (Stanford University Medical Center)	Dr. Dunn has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Dunn has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme. The institution of Dr. Dunn has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Progentec Diagnostics. Dr. Dunn has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna Therapeutics. Dr. Dunn has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��